PETACH TIKVA, Israel,
June 15, 2017 /PRNewswire/
-- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a
biotechnology company advancing a pipeline of proprietary small
molecule drugs that address cancer, liver and inflammatory
diseases, announced today that the Company's CEO Dr. Pnina Fishman will participate in the Bio
International Convention, which will take place on June 19 through 22, 2017 in San Diego, California. Dr. Fishman is
scheduled to take part in over 40 one-on-one meetings with
potential partners including companies interested in Can-Fite's
drug candidates for in-licensing and commercialization.
"Our two advanced stage drug candidates, Piclidenoson for
auto-immune diseases and Namodenoson for cancer and liver diseases,
address significant unmet needs in global markets. Having
successfully entered into a select few strategic geographic
distribution partnerships, we are evaluating additional
out-licensing opportunities as we move into Phase III studies,"
stated Dr. Fishman.
The BIO International Convention is hosted by the Biotechnology
Innovation Organization (BIO). BIO represents more than 1,100
biotechnology companies, academic institutions, state biotechnology
centers and related organizations across the United States and in more than 30 other
nations.
About Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI) is an
advanced clinical stage drug development Company with a platform
technology that is designed to address multi-billion dollar markets
in the treatment of cancer, inflammatory disease and sexual
dysfunction. The Company's lead drug candidate, Piclidenoson, is
scheduled to enter Phase III trials in 2017 for two indications,
rheumatoid arthritis and psoriasis. The rheumatoid arthritis Phase
III protocol has recently been agreed with the European Medicines
Agency. Can-Fite's liver cancer drug Namodenoson is in Phase II
trials for patients with liver cancer and is slated to enter Phase
II for the treatment of non-alcoholic steatohepatitis (NASH).
Namodenoson has been granted Orphan Drug Designation in the U.S.
and Europe and Fast Track
Designation as a second line treatment for hepatocellular carcinoma
by the U.S. Food and Drug Administration. Namodenoson has also
shown proof of concept to potentially treat other cancers including
colon, prostate, and melanoma. CF602, the Company's third drug
candidate, has shown efficacy in the treatment of erectile
dysfunction in preclinical studies and is being prepared for an IND
submission to the FDA and a Phase I trial. These drugs have
an excellent safety profile with experience in over 1,000 patients
in clinical studies to date. For more information please visit:
www.can-fite.com.
Forward-Looking Statements
This press release may contain forward-looking statements, about
Can-Fite's expectations, beliefs or intentions regarding, among
other things, market risks and uncertainties and Can-Fite's ability
to satisfy all the conditions to the closing of the proposed
offering, its product development efforts, business, financial
condition, results of operations, strategies or prospects. In
addition, from time to time, Can-Fite or its representatives have
made or may make forward-looking statements, orally or in writing.
Forward-looking statements can be identified by the use of
forward-looking words such as "believe," "expect," "intend,"
"plan," "may," "should" or "anticipate" or their negatives or other
variations of these words or other comparable words or by the fact
that these statements do not relate strictly to historical or
current matters. These forward-looking statements may be included
in, but are not limited to, various filings made by Can-Fite with
the U.S. Securities and Exchange Commission, press releases or oral
statements made by or with the approval of one of Can-Fite's
authorized executive officers. Forward-looking statements relate to
anticipated or expected events, activities, trends or results as of
the date they are made. Because forward-looking statements relate
to matters that have not yet occurred, these statements are
inherently subject to risks and uncertainties that could cause
Can-Fite's actual results to differ materially from any future
results expressed or implied by the forward-looking statements.
Many factors could cause Can-Fite's actual activities or results to
differ materially from the activities and results anticipated in
such forward-looking statements, including, but not limited to, the
factors summarized in Can-Fite's filings with the SEC and in its
periodic filings with the TASE. In addition, Can-Fite operates in
an industry sector where securities values are highly volatile and
may be influenced by economic and other factors beyond its control.
Can-Fite does not undertake any obligation to publicly update these
forward-looking statements, whether as a result of new information,
future events or otherwise.
Contact
Can-Fite BioPharma
Motti Farbstein
info@canfite.com
+972-3-9241114
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/can-fite-to-participate-in-bio-international-convention-in-san-diego-on-june-19-22-2017-300474366.html
SOURCE Can-Fite BioPharma Ltd.